Veru to Present at 17th International Conference on Sarcopenia and Cachexia
Veru Inc. has exciting news to share! The company, a late-stage biopharmaceutical company dedicated to developing innovative medicines, will be presenting at the 17th International Conference of the Society on Sarcopenia, Cachexia, and Wasting Disorders. This event is scheduled to take place from December 6-8, 2024, in Washington, DC.
The presentation is titled “The use of muscle-selective anabolics to make GLP-1 RA weight loss drugs more effective and precise” and is set for Friday, December 6th, 2024, from 4:15 PM to 5:30 PM Eastern Standard Time. The event location is in Washington DC, USA. You can find more details about the meeting on their website.
One of the key highlights of this presentation will be an update on the Enobosarm Phase 2b QUALITY clinical trial. This trial aims to evaluate the safety and efficacy of enobosarm in preserving muscle and enhancing fat loss in patients with sarcopenic obesity or overweight elderly patients over 60 years of age who are receiving semaglutide (Wegovy®).
The primary endpoint of the trial is total lean body mass, with key secondary endpoints including total body fat mass and physical function as measured by a stair climb test at the 16-week mark. We eagerly anticipate the release of topline clinical results in January 2025.
Following the completion of the Phase 2b QUALITY clinical trial, participants are expected to move into a Phase 2b extension clinical trial. In this trial, patients will discontinue the GLP-1 RA medication but continue to take placebo, enobosarm 3mg, or enobosarm 6mg for an additional 12 weeks. This extension study aims to determine if enobosarm can help in maintaining muscle and preventing fat and weight gain after stopping a GLP-1 RA medication. We can expect to see the results of this extension study in the second quarter of 2025.
Sarcopenic obesity is a prevalent issue, with a significant percentage of older adults in the United States affected by this condition. In fact, up to 34.4% of obese individuals over 60 years of age suffer from sarcopenic obesity. These patients are at risk when taking GLP-1 RA drugs for weight loss due to their already low muscle mass caused by age-related muscle loss. The use of GLP-1 RA drugs may further accelerate muscle loss and lead to frailty and other health issues.
Enobosarm, also known as ostarine, MK-2866, GTx-024, and VERU-024, holds promise in addressing these challenges and helping patients with sarcopenic obesity. Stay tuned for more updates on this promising development in the field of biopharmaceuticals.
